Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does POMALIDOMIDE Cause Systemic inflammatory response syndrome? 10 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 10 reports of Systemic inflammatory response syndrome have been filed in association with POMALIDOMIDE (Pomalyst). This represents 0.0% of all adverse event reports for POMALIDOMIDE.

10
Reports of Systemic inflammatory response syndrome with POMALIDOMIDE
0.0%
of all POMALIDOMIDE reports
3
Deaths
8
Hospitalizations

How Dangerous Is Systemic inflammatory response syndrome From POMALIDOMIDE?

Of the 10 reports, 3 (30.0%) resulted in death, 8 (80.0%) required hospitalization.

Is Systemic inflammatory response syndrome Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for POMALIDOMIDE. However, 10 reports have been filed with the FAERS database.

What Other Side Effects Does POMALIDOMIDE Cause?

Plasma cell myeloma (7,023) Death (6,795) Fatigue (6,530) Pneumonia (5,792) Off label use (3,845) Diarrhoea (3,351) White blood cell count decreased (3,328) Neutropenia (3,029) Rash (2,715) Dyspnoea (2,543)

What Other Drugs Cause Systemic inflammatory response syndrome?

DOXORUBICIN (161) METHOTREXATE (158) CYCLOPHOSPHAMIDE (153) CYTARABINE (153) METHYLPREDNISOLONE (117) ADALIMUMAB (107) RITUXIMAB (106) PREDNISOLONE (99) VINCRISTINE (97) MYCOPHENOLATE MOFETIL (95)

Which POMALIDOMIDE Alternatives Have Lower Systemic inflammatory response syndrome Risk?

POMALIDOMIDE vs POMALYST POMALIDOMIDE vs PONATINIB POMALIDOMIDE vs PONATINIB\PONATINIB POMALIDOMIDE vs PONESIMOD POMALIDOMIDE vs PORACTANT ALFA

Related Pages

POMALIDOMIDE Full Profile All Systemic inflammatory response syndrome Reports All Drugs Causing Systemic inflammatory response syndrome POMALIDOMIDE Demographics